Compare BZUN & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZUN | KZIA |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.5M | 186.7M |
| IPO Year | 2014 | 2002 |
| Metric | BZUN | KZIA |
|---|---|---|
| Price | $3.60 | $7.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $4.58 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 369.5K | 229.9K |
| Earning Date | 11-24-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.08 | N/A |
| Revenue Next Year | $7.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.07 | $4.86 |
| 52 Week High | $3.92 | $17.40 |
| Indicator | BZUN | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 59.76 | 37.13 |
| Support Level | $2.57 | $6.72 |
| Resistance Level | N/A | $8.18 |
| Average True Range (ATR) | 0.22 | 0.68 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 56.08 | 40.26 |
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.